PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.89%
Revenue growth above 1.5x ADI's 3.63%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
14.06%
Gross profit growth above 1.5x ADI's 5.51%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
32.73%
EBIT growth above 1.5x ADI's 14.51%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
32.73%
Operating income growth above 1.5x ADI's 14.51%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
308.03%
Net income growth above 1.5x ADI's 20.96%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
316.22%
EPS growth above 1.5x ADI's 21.21%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
316.67%
Diluted EPS growth above 1.5x ADI's 21.88%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-2.02%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.98%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.07%
Dividend reduction while ADI stands at 0.75%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
14.72%
OCF growth at 75-90% of ADI's 17.05%. Bill Ackman would demand better working capital management or cost discipline.
77.85%
FCF growth above 1.5x ADI's 13.83%. David Dodd would verify if the firm’s strategic investments yield superior returns.
50.46%
10Y revenue/share CAGR at 50-75% of ADI's 97.27%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
109.30%
5Y revenue/share CAGR above 1.5x ADI's 5.44%. David Dodd would look for consistent product or market expansions fueling outperformance.
75.93%
3Y revenue/share CAGR above 1.5x ADI's 28.31%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
278.11%
10Y OCF/share CAGR under 50% of ADI's 1412.92%. Michael Burry would worry about a persistent underperformance in cash creation.
25.75%
Positive OCF/share growth while ADI is negative. John Neff might see a comparative advantage in operational cash viability.
88.16%
3Y OCF/share CAGR similar to ADI's 91.29%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
2966.45%
Net income/share CAGR above 1.5x ADI's 207.97% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
1497.30%
5Y net income/share CAGR above 1.5x ADI's 40.13%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
2095.75%
3Y net income/share CAGR above 1.5x ADI's 104.52%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
191.78%
10Y equity/share CAGR at 50-75% of ADI's 353.12%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
16.42%
Below 50% of ADI's 35.44%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
30.08%
3Y equity/share CAGR above 1.5x ADI's 19.22%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
42.42%
Dividend/share CAGR of 42.42% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
46.49%
Dividend/share CAGR of 46.49% while ADI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
41.39%
3Y dividend/share CAGR of 41.39% while ADI is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
7.29%
AR growth well above ADI's 12.64%. Michael Burry fears inflated revenue or higher default risk in the near future.
7.14%
Inventory growth well above ADI's 6.39%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
13.46%
Asset growth above 1.5x ADI's 0.67%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
16.14%
Positive BV/share change while ADI is negative. John Neff sees a clear edge over a competitor losing equity.
-86.48%
We’re deleveraging while ADI stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
0.56%
R&D growth drastically higher vs. ADI's 0.43%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-0.71%
We cut SG&A while ADI invests at 1.20%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.